Genomics

Dataset Information

0

A Phase II Trial of High Dose Interleukin-2 and Multi-site Stereotactic Ablative Radiotherapy for Patients with Metastatic Renal Cell Carcinoma


ABSTRACT: Immune-based therapies have improved outcomes for metastatic renal cell carcinoma (mRCC) but there is still a significant margin for improvement. Here, we report the results of a phase II trial combining high dose Interleukin-2 (HD-IL-2) with stereotactic ablative body radiotherapy (SAbR) for patients with metastatic renal cell carcinoma.

PROVIDER: EGAS00001003605 | EGA |

REPOSITORIES: EGA

Similar Datasets

2010-08-17 | GSE23633 | GEO
| PRJNA349174 | ENA
| PRJNA172767 | ENA
2010-08-19 | GSE23690 | GEO
2019-09-30 | GSE135091 | GEO
2012-08-13 | E-GEOD-39440 | biostudies-arrayexpress
2010-08-17 | E-GEOD-23633 | biostudies-arrayexpress
2023-12-28 | PXD039106 | JPOST Repository
2012-08-14 | GSE39440 | GEO
2010-08-19 | E-GEOD-23690 | biostudies-arrayexpress